Suppr超能文献

舒他西林颗粒在儿科领域的药代动力学及临床研究

[Pharmacokinetic and clinical studies of sultamicillin granule in the pediatric field].

作者信息

Motohiro T, Sakata Y, Aramaki M, Oda K, Kawakami A, Tanaka K, Koga T, Fujimoto T, Yamashita F, Takajo N

机构信息

Department of Pediatrics, School of Medicine, Kurume University.

出版信息

Jpn J Antibiot. 1988 Dec;41(12):1980-2000.

PMID:3249372
Abstract

Sultamicillin (SBTPC) is a combined drug of ampicillin (ABPC) and sulbactam (SBT) which is an inhibitor of beta-lactamase, in a clinical form of tosylate with equivalent molecules in ester linkages. A tablet form of this combined drug has been released since July, 1987 in Japan and now a granular form for pediatric patients has been developed. Hence, the granular form of SBTPC was administered to 6 boys (age: 8 years 5 months-11 years 5 months) to determine plasma and urinary concentrations of the drug and its urinary recovery-rates. The dose of 10 mg/kg or 15 mg/kg was given orally just after meal to 3 boys. To study clinical and bacteriological effects of this drug, a mean daily dose of 27.1 mg/kg divided 2-4 times a day was administered for 9 days on the average to a total of 57 cases with pharyngitis (5), tonsillitis (5), laryngitis (1), bronchitis (1), pneumonia (8), scarlet fever (1), typhoid fever (1), impetigo (16), furuncle (2), abscess (6), lymphadenitis (1) and urinary tract infection (10) except 2 cases which were unevaluable for clinical effects. MICs of 7 drugs (SBTPC, ABPC, SBT, methicillin (DMPPC), cloxacillin (MCIPC), cephalexin and cefaclor) against 12 of 22 strains isolated from patients with infections of skin and soft tissue were determined with inoculum-sizes of 10(8) and 10(8) CFU/ml to study beta-lactamase producing activities. Adverse reactions and abnormal effects on laboratory test values attributable to this drug were studied in patients including dropped-out cases. The results obtained are summarized as follows. 1. Mean plasma peak levels of ABPC and SBT were observed at 1 hour after administration in both of the 10 mg/kg and the 15 mg/kg groups with values of 2.34 and 5.57 micrograms/ml for ABPC and 1.87 and 4.66 micrograms/ml for SBT, respectively. Mean concentrations of SBT were lower than those of ABPC in both groups and individuals. Dose-responses in plasma levels and AUCs were observed in both groups. Mean half-life values of ABPC and SBT in the 2 groups were 1.93 and 1.12 hours for ABPC and 1.97 and 1.22 for SBT, respectively. Mean half-life values for ABPC and SBT were similar in each group and this tendency was also seen among individuals.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

舒他西林(SBTPC)是氨苄西林(ABPC)和β-内酰胺酶抑制剂舒巴坦(SBT)的复方制剂,临床剂型为甲苯磺酸盐,酯键连接的分子当量。该复方制剂的片剂自1987年7月起在日本上市,目前已开发出儿科患者用颗粒剂。因此,对6名男孩(年龄:8岁5个月至11岁5个月)给予舒他西林颗粒剂,以测定药物的血浆和尿液浓度及其尿回收率。3名男孩餐后口服剂量为10mg/kg或15mg/kg。为研究该药物的临床和细菌学效果,对总共57例咽炎(5例)、扁桃体炎(5例)、喉炎(1例)、支气管炎(1例)、肺炎(8例)、猩红热(1例)、伤寒(1例)、脓疱病(16例)、疖(2例)、脓肿(6例)、淋巴结炎(1例)和尿路感染(10例)患者平均每天给予27.1mg/kg、分2至4次给药,平均给药9天,但有2例患者临床效果无法评估。测定了7种药物(舒他西林、氨苄西林、舒巴坦、甲氧西林(DMPPC)、氯唑西林(MCIPC)、头孢氨苄和头孢克洛)对从皮肤和软组织感染患者中分离出的22株菌株中的12株的最低抑菌浓度(MIC),接种量分别为10⁸和10⁸CFU/ml,以研究β-内酰胺酶产生活性。在包括退出病例在内的患者中研究了该药物引起的不良反应和对实验室检查值的异常影响。所得结果总结如下。1. 在10mg/kg和15mg/kg组中,给药后1小时均观察到氨苄西林和舒巴坦的平均血浆峰浓度,氨苄西林分别为2.34和5.57μg/ml,舒巴坦分别为1.87和4.66μg/ml。两组及个体中舒巴坦的平均浓度均低于氨苄西林。两组均观察到血浆浓度和药时曲线下面积(AUC)的剂量反应。两组中氨苄西林和舒巴坦的平均半衰期值分别为氨苄西林1.93和1.12小时,舒巴坦1.97和1.22小时。每组中氨苄西林和舒巴坦的平均半衰期值相似,个体间也有此趋势。(摘要截短至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验